A diagnostic framework that categorizes ADHD patients into clinical subgroups based on specific dopaminergic signaling markers rather than a one-size-fits-all diagnosis.
The PESTEL analysis reveals a high-potential opportunity driven by a shift toward precision medicine and strong pharmaceutical interest, though it faces significant hurdles in regulatory approval and the high cost of biomarker validation. The success of the tool depends on transitioning from behavioral-only diagnostics to a biologically validated clinical standard.
Political2
Economic3
Social2
Technological2
Environmental2
Legal3
The viability of a clinical diagnostic tool is heavily dependent on medical regulations, healthcare laws, and technological advancements in biomarker detection. · Generated 2026-10-02 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated